Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine

Abstract

Coronavirus infectious disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused significant global morbidity and mortality since first emerging as a pathogen at the end of 2019. Acute kidney injury, most commonly due to acute tubular injury, is a frequent finding in COVID-19, occurring in 17% to 37% of patients.1–3 De novo glomerular disease is much less common with COVID-19, although cases of new-onset collapsing glomerulopathy, immune-complex glomerulonephritis, and antineutrophil cytoplasmic autoantibody (ANCA)–associated glomerulonephritis have been reported.